Posts by Mourabit Halima

The 39th Annual European Association of Urology (EAU24) Congress took place from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and the forefront of Chinese urological research. At the event, "Oncology Frontier" invited Professor Wei Zhai from Renji Hospital, affiliated with Shanghai Jiao Tong University School o,(f Medicine, to share his insights and the latest developments in urological oncology research.

HR+/HER2- is the most common subtype of breast cancer, which is not highly sensitive to neoadjuvant therapy. In 2023, clinical trial results from KEYNOTE-756, CheckMate 7FL, and other studies presented at international conferences showed the potential of neoadjuvant immunotherapy for early-stage HR+/HER2- breast cancer patients. At the 2024 North-South Summit, Professor Leiping Wang from Fudan University Cancer Hospital delivered a report titled "HR+/HER2- Breast Cancer: Entering the Era of Neoadjuvant Immunotherapy?" This article reviews the content of her lecture for readers.

Among breast cancer patients, 5% to 10% have definite genetic mutations, with gBRCA1/2 mutations accounting for 15% of these cases. Individuals with gBRCA1 mutations have a higher risk of contralateral breast cancer recurrence, making the decision to undergo contralateral prophylactic mastectomy (CPM) a hot topic of discussion. At the 2024 North-South Summit, Professor Jia Wang from The Second Affiliated Hospital of Dalian Medical University delivered a report titled "gBRCA-Mutated Breast Cancer: Should Contralateral Prophylactic Mastectomy Be Considered?" This article reviews the content of the lecture.

With the continuous development and market release of new ADC drugs, the treatment landscape for breast cancer patients has changed. For patients with advanced breast cancer, the feasibility of using another ADC drug after the initial ADC treatment has become a common clinical concern. In the "In-depth Inquiry" segment of the 2024 North-South Meeting, Professor Ting Luo from West China Hospital of Sichuan University delivered a report titled "Rescue Treatment for Advanced Breast Cancer: ADC After ADC?". This article reviews the content of her lecture.

Urothelial carcinoma is one of the most common malignancies of the urinary system, with high incidence and mortality rates. Despite the efficacy of platinum-based chemotherapy as the standard first-line treatment for advanced urothelial carcinoma, researchers have been relentless in their pursuit of more effective and personalized treatment options. Recent breakthroughs in targeted therapies and immunotherapies have spurred the development of various combination therapies, bringing new hope to patients with advanced urothelial carcinoma. At the recently concluded 39th Annual Congress of the European Association of Urology (EAU24), Oncology Frontier had the privilege of interviewing Professor Thomas Powles from the University of London and Barts Cancer Institute. In this interview, Professor Powles detailed the current status and challenges in the field of advanced urothelial carcinoma, as well as future directions worth exploring.

The prevalence of robotic surgery in the treatment of early-stage breast cancer is not high, and there is significant debate over its necessity for these patients. At the 2024 South-North Forum, Prof. Li Ma from The Fourth Hospital of Hebei Medical University delivered a presentation on the topic "Is Robotic Surgery Necessary for Early-Stage Breast Cancer?" This article reviews the key points from his lecture.

The treatment of renal cancer includes surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. With advancements in treatment technologies, combining the latest modalities for comprehensive treatment of renal cancer is crucial for improving prognosis. The 39th Annual European Association of Urology (EAU24) Congress was held from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and forefront advancements from Chinese urological scholars. "Oncology Frontier" had the opportunity to interview Professor Qiang Wei from West China Hospital, Sichuan University, who shared insights into adjuvant immunotherapy for renal cancer, cytoreductive nephrectomy research, and robot-assisted radical nephrectomy.